CARsgen wins first global approval of CAR T therapy for solid tumours

CE2026-06-23T10:19:00

Source:

Approval of the autologous cell therapy satri-cel in China fills the gap in later-line treatment for advanced gastric cancer.

Now approved in China, CARsgen Therapeutics’ satricabtagene autoleucel (satri-cel) is the first CAR T therapy to secure global approval in a solid tumour, setting a new standard for this form of treatment.

The autologous treatment is indicated for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in those who…

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member